Alterity Therapeutics Says FDA Backs Phase 3 Design for Multiple System Atrophy Therapy
() -- Alterity Therapeutics (ATHE) said Tuesday the US Food and Drug Administration's end-of-phase 2 meeting minutes confirmed agreement on the key elements of the registrational phase 3 trial for ATH434 in multiple system atrophy. The company said the FDA agreed with the proposed phase 3 design, including the study po